@FierceBiotech: Special Report: Top 15 blockbuster contenders in the biopharma pipeline. Report | Follow @FierceBiotech
@JohnCFierce: Yesterday Lilly's CEO piously talked about measuring value by patient benefit. And how does Xigris do on that score? Release | Follow@JohnCFierce
@RyanMFierce: Guess which Big Pharma is developing 3 of Fierce's 15 top blockbuster contenders mal;">Report | Follow @RyanMFierce
@MaureenFierce: Good to remember: If you want to start a company based on research done at your institution without a license you can get thrown in jail. | Follow @MaureenFierce
> Exelixis ($EXEL) named J. Scott Garland as executive vice president and chief commercial officer. Garland is a Genentech vet, Genentech, where he served as vice president of its Avastin franchise. Release
> Marlborough, MA-based Acton Pharmaceuticals has inked a licensing pact with Sanofi ($SNY) that will clear the way to bring a nasal spray for allergic rhinitis to the U.S. market. Report
> Just a couple of weeks after expanding its Series A round, Foundation Medicine announced its fourth collaboration with Johnson & Johnson Pharmaceutical Research and Development. Release
Pharma News
@FiercePharma: More in-demand #pharma jobs: med communications, which includes medical writing, editing, graphic design and science journalism. #AAPS2011 | Follow @FiercePharma
> Roche offers money-back deal on Avastin in Germany. News
> Novartis cost push claims 2,000 jobs in U.S., Switzerland. Report
> Amgen sets aside $780M for marketing settlement. Item
> Lilly pulls Xigris on failed septic-shock study. Article
> Collins: NIH targeting bottlenecks in drug development process. Report
Biotech Research News
> Biotech founder counters the skeptics with anti-aging program. Story
> Nanotech team at Stanford develops artificial super skin. More
> Antibody guards primates against lethal Hendra virus. Article
> Human studies of swine tissue transplants loom closer. Piece
> Small ALS stem cell study takes a big step forward. News
Manufacturing News
> 'Little things' blossomed into big QA trouble at J&J/McNeil. Article
> APP, Hospira resolve shortage of cytarabine. Item
> Actavis shipment of opioids stolen from truck stop. Report
> Astellas recall triggered by excess API in capsules. More
> Sanofi manufacturing glitch yields insulin pen shortage. Item
> Woodcock: More predictable manufacturing may ease regulations. Story
And Finally... The prestigious Rand Corp. says it will examine its review process after deciding to retract a bungled report on pot clinics and crime. Story